Four monocytic KMT2A-r LS AML data samples were obtained from the study reported by Tirtakusuma et al.10, and 49 monocytic KMT2A-r LC AML data samples (40 at disease presentation, nine at relapse) were collected from the data matrix of the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) AML initiative (https://www.cancer.gov/ccg/research/genome-sequencing/target)14. This evidence concerns the gene KMT2A and acute myeloid leukemia.